Tim Anderson
Stock Analyst at B of A Securities
(4.16)
# 448
Out of 4,944 analysts
37
Total ratings
71.43%
Success rate
9.72%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $27 → $28 | $24.65 | +13.59% | 2 | Aug 6, 2025 | |
| AMGN Amgen | Maintains: Underperform | $252 → $261 | $284.98 | -8.41% | 5 | Jul 23, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $161 → $175 | $172.78 | +1.28% | 6 | Jul 17, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $556.56 | -1.72% | 2 | Apr 17, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $22 → $26 | $10.04 | +158.96% | 2 | Mar 27, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $120.02 | +4.98% | 3 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $198.64 | +12.26% | 5 | Mar 4, 2025 | |
| MTSR Metsera | Initiates: Buy | $38 | $30.88 | +23.06% | 1 | Feb 25, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $25.66 | +32.50% | 2 | Feb 11, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $118 → $112 | $80.30 | +39.48% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $46.55 | +35.34% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $128.93 | +38.06% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $639.43 | +55.92% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $119.31 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $75.34 | - | 1 | Sep 22, 2017 |
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $27 → $28
Current: $24.65
Upside: +13.59%
Amgen
Jul 23, 2025
Maintains: Underperform
Price Target: $252 → $261
Current: $284.98
Upside: -8.41%
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $161 → $175
Current: $172.78
Upside: +1.28%
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $556.56
Upside: -1.72%
Aardvark Therapeutics
Mar 27, 2025
Maintains: Buy
Price Target: $22 → $26
Current: $10.04
Upside: +158.96%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $120.02
Upside: +4.98%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $198.64
Upside: +12.26%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $38
Current: $30.88
Upside: +23.06%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $25.66
Upside: +32.50%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $80.30
Upside: +39.48%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $46.55
Upside: +35.34%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $128.93
Upside: +38.06%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $639.43
Upside: +55.92%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $119.31
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $75.34
Upside: -